|
PT90657B
(pt)
|
1988-05-27 |
1995-03-01 |
Ortho Pharma Corp |
Processo para a preparacao de peptidos que bloqueiam a ligacao de hiv-1 a proteina cd4 receptora
|
|
JPH0768273B2
(ja)
*
|
1988-12-02 |
1995-07-26 |
カルピス食品工業株式会社 |
抗ｈｉｖペプチド
|
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
|
IL162181A
(en)
|
1988-12-28 |
2006-04-10 |
Pdl Biopharma Inc |
A method of producing humanized immunoglubulin, and polynucleotides encoding the same
|
|
AU5656890A
(en)
|
1989-05-02 |
1990-11-29 |
Genelabs Incorporated |
Chemically modified cd4 peptide fragments having anti-retroviral properties
|
|
US5690933A
(en)
|
1989-05-31 |
1997-11-25 |
Glaxo Wellcome Inc. |
Monoclonal antibodies for inducing tolerance
|
|
GB8912497D0
(en)
|
1989-05-31 |
1989-07-19 |
Cobbold Stephen P |
Monoclonal antibodies
|
|
GB8928874D0
(en)
|
1989-12-21 |
1990-02-28 |
Celltech Ltd |
Humanised antibodies
|
|
US5859205A
(en)
|
1989-12-21 |
1999-01-12 |
Celltech Limited |
Humanised antibodies
|
|
US20020099179A1
(en)
|
1989-12-21 |
2002-07-25 |
Linda K. Jolliffe |
Cdr-grafted antibodies
|
|
HUT60768A
(en)
|
1990-03-16 |
1992-10-28 |
Sandoz Ag |
Process for producing cd25 fixing molecules
|
|
US7084260B1
(en)
|
1996-10-10 |
2006-08-01 |
Genpharm International, Inc. |
High affinity human antibodies and human antibodies against human antigens
|
|
AU662891B2
(en)
|
1990-11-27 |
1995-09-21 |
Biogen Idec Ma Inc. |
Anti CD-4 antibodies blocking HIV-induced syncytia
|
|
US7192584B2
(en)
|
1991-03-18 |
2007-03-20 |
Centocor, Inc. |
Methods of treating psoriasis with anti-TNF antibodies
|
|
US6136310A
(en)
|
1991-07-25 |
2000-10-24 |
Idec Pharmaceuticals Corporation |
Recombinant anti-CD4 antibodies for human therapy
|
|
JPH05244982A
(ja)
|
1991-12-06 |
1993-09-24 |
Sumitomo Chem Co Ltd |
擬人化ｂ−ｂ１０
|
|
US5777085A
(en)
|
1991-12-20 |
1998-07-07 |
Protein Design Labs, Inc. |
Humanized antibodies reactive with GPIIB/IIIA
|
|
IL101769A
(en)
|
1992-05-03 |
2007-02-11 |
Yeda Res & Dev |
Modulation of TNF receptor action
|
|
WO1994008619A1
(en)
|
1992-10-08 |
1994-04-28 |
The Kennedy Institute Of Rheumatology |
Treatment of autoimmune and inflammatory disorders
|
|
WO1995009652A1
(en)
|
1993-10-06 |
1995-04-13 |
The Kennedy Institute For Rheumatology |
Treatment of autoimmune and inflammatory disorders
|
|
US6270766B1
(en)
|
1992-10-08 |
2001-08-07 |
The Kennedy Institute Of Rheumatology |
Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease
|
|
EP0614984B2
(en)
|
1993-03-05 |
2010-11-03 |
Bayer HealthCare LLC |
Anti-TNF alpha human monoclonal antibodies
|
|
EP0631783A1
(en)
|
1993-06-03 |
1995-01-04 |
Mitsubishi Chemical Corporation |
Antiviral combinations of 2',3'-di-deoxyribonucleosides with 6-benzyl-1-ethoxymethyl-5-substituted uracil derivatives
|
|
US20020068057A1
(en)
|
1994-03-10 |
2002-06-06 |
Marc Feldmann |
Treatment of autoimmune and inflammatory disorders
|
|
EP1161955A3
(en)
|
1995-05-18 |
2001-12-19 |
Ortho Pharmaceutical Corporation |
Induction of immunological tolerance for graft transplantation by the use of humanized non-depleting anti-cd4 antibodies in combination with specific donor bone marrow cells
|
|
HU230048B1
(hu)
|
1996-02-09 |
2015-06-29 |
Abbvie Biotechnology Ltd |
Humán TNFalfa-kötő antitestek alkalmazása
|
|
US20010056066A1
(en)
|
1996-07-26 |
2001-12-27 |
Smithkline Beecham Corporation |
Method of treating immune cell mediated systemic diseases
|
|
WO1998014211A1
(en)
|
1996-10-01 |
1998-04-09 |
Celltech Therapeutics Limited |
Pharmaceutical products containing protein-tyrosine kinase inhibitors and anti-cd4 antibodies
|
|
US6037454A
(en)
|
1996-11-27 |
2000-03-14 |
Genentech, Inc. |
Humanized anti-CD11a antibodies
|
|
DE19722888A1
(de)
|
1997-05-28 |
1998-12-03 |
Thomas Prof Dr Huenig |
Human-CD28 spezifische monoklonale Antikörper zur antigenunspezifischen Aktivierung von T-Lymphozyten
|
|
AU3633000A
(en)
|
1999-03-26 |
2000-10-16 |
Human Genome Sciences, Inc. |
Neutrokine-alpha binding proteins and methods based thereon
|
|
EP1194167B1
(en)
|
1999-06-09 |
2009-08-19 |
Immunomedics, Inc. |
Immunotherapy of autoimmune disorders using antibodies which target b-cells
|
|
AU6941000A
(en)
*
|
1999-08-27 |
2001-03-26 |
United States Of America, Represented By The Secretary, Department Of Health And Human Services, The |
Polypeptides that bind hiv gp120 and related nucleic acids, antibodies, compositions, and methods of use
|
|
US7304127B2
(en)
|
1999-08-27 |
2007-12-04 |
United States Of America As Represented By The Secretary, Department Of Health And Human Services |
Polypeptides that bind HIV gp120 and related nucleic acids, antibodies, compositions, and methods of use
|
|
AU2001275186A1
(en)
|
2000-06-02 |
2001-12-17 |
Nicole Kirchhof |
Immunotherapeutic method to prevent islet cell rejection
|
|
US20020058029A1
(en)
|
2000-09-18 |
2002-05-16 |
Nabil Hanna |
Combination therapy for treatment of autoimmune diseases using B cell depleting/immunoregulatory antibody combination
|
|
DE10050935A1
(de)
|
2000-10-11 |
2002-05-02 |
Tegenero Gmbh |
Verwendung CD28 spezifischer monoklonaler Antikörper zur Stimulation von Blutzellen, welche kein CD28 tragen
|
|
AU2002249958B2
(en)
|
2001-01-16 |
2007-11-08 |
Vascular Therapies, Inc. |
Implantable device containing resorbable matrix material and anti-proliferative drugs for preventing or treating failure of hemodialysis vascular access and other vascular grafts
|
|
CA2440649A1
(en)
|
2001-03-07 |
2002-09-19 |
Children's Medical Center Corporation |
Method to screen peptide display libraries using minicell display
|
|
EP1241249A1
(en)
|
2001-03-12 |
2002-09-18 |
Gerold Schuler |
CD4+CD25+regulatory T cells from human blood
|
|
ES2366775T3
(es)
|
2001-04-24 |
2011-10-25 |
Merck Patent Gmbh |
POLITERAPIA UTILIZANDO AGENTES ANTIANGIOGÉNICOS Y TNF(alfa).
|
|
GB2376466A
(en)
|
2001-06-14 |
2002-12-18 |
Mark Frewin |
TRX1 antibody
|
|
US7541443B2
(en)
|
2001-06-14 |
2009-06-02 |
Tolerrx, Inc. |
Anti-CD4 antibodies
|
|
EP1395284B1
(en)
|
2001-06-14 |
2010-12-08 |
Isis Innovation Limited |
Non-depleting anti-CD4 antibody TRX1 and its uses
|
|
DK1451224T3
(da)
|
2001-12-04 |
2012-11-19 |
Theramab Llc |
Peptid eller protein, der indeholder en C´-D-sløjfe fra CD28-receptorfamilien
|
|
DE10212108A1
(de)
|
2002-03-13 |
2003-10-02 |
Tegenero Ag |
Verwendung einer an CD28 bindenden Wirksubstanz zur Herstellung einer pharmazeutischen Zusammensetzung
|
|
DE10230223A1
(de)
|
2002-07-04 |
2004-01-22 |
Tegenero Ag |
Mikropartikel mit CD28-spezifischen monoklonalen Antikörpern
|
|
EP1578364A4
(en)
|
2002-09-16 |
2011-06-08 |
Genentech Inc |
COMPOSITIONS AND METHOD FOR THE TREATMENT OF ILLNESSES OF THE IMMUNE SYSTEM
|
|
US7388079B2
(en)
*
|
2002-11-27 |
2008-06-17 |
The Regents Of The University Of California |
Delivery of pharmaceutical agents via the human insulin receptor
|
|
US7501494B2
(en)
|
2003-01-15 |
2009-03-10 |
United Biomedical, Inc. |
Designed deimmunized monoclonal antibodies for protection against HIV exposure and treatment of HIV infection
|
|
EP1460088A1
(en)
*
|
2003-03-21 |
2004-09-22 |
Biotest AG |
Humanized anti-CD4 antibody with immunosuppressive properties
|
|
SI1613350T1
(sl)
|
2003-04-09 |
2009-08-31 |
Genentech Inc |
Zdravljenje avtoimunske bolezni pri bolniku z neustreznim odzivom na inhibitor TNF-alfa
|
|
GB0314461D0
(en)
|
2003-06-20 |
2003-07-23 |
Isis Innovation |
Suppression of transplant rejection
|
|
US7691970B2
(en)
|
2003-08-25 |
2010-04-06 |
Pieris Ag |
Muteins of a bilin-binding protein with affinity for a given target
|
|
EP1600164A3
(de)
|
2003-09-22 |
2006-05-17 |
TeGenero AG |
Verwendung einer an CD28 bindenden Wirksubstanz zur Herstellung einer Pharmazeutischen Zusammensetzung mit dosisabhängiger Wirkung
|
|
DE10352900A1
(de)
|
2003-11-11 |
2005-06-16 |
Tegenero Ag |
Verwendung einer an CD28 bindenden Wirksubstanz zur Herstellung einer pharmazeutischen Zusammensetzung zur Behandlung von B-CLL
|
|
RU2007102055A
(ru)
|
2004-06-22 |
2008-07-27 |
Толерркс, Инк. (Us) |
Оптимизированное введение доз анти-cd4-антител для индукции толерантности у приматов
|
|
RU2007104022A
(ru)
|
2004-07-02 |
2008-08-10 |
Дженентек, Инк. (Us) |
Композиции для лечения неходжкинской лимфомы и способы их применения
|
|
CN101031305A
(zh)
|
2004-09-29 |
2007-09-05 |
兴和株式会社 |
类风湿性关节炎的预防和/或治疗药物
|
|
EP2171060B1
(de)
|
2004-11-11 |
2013-10-02 |
TheraMAB LLC |
Superagonistische anti-cd28 antikörper
|
|
WO2006055077A2
(en)
|
2004-11-12 |
2006-05-26 |
The University Of North Carolina At Charlotte |
Modulation of cd4+ t cell responses by a tick saliva protein, salp15 and polypeptides derived therefrom
|
|
DE102004063494A1
(de)
|
2004-12-23 |
2006-07-13 |
Tegenero Ag |
Antikörper
|
|
JP4730733B2
(ja)
|
2005-05-02 |
2011-07-20 |
国立大学法人京都大学 |
４型葉酸受容体の発現を指標とした制御性ｔ細胞の検出方法、及び免疫賦活剤
|
|
AU2006267090B2
(en)
|
2005-07-11 |
2013-03-07 |
Provention Bio, Inc. |
Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity
|
|
AU2006281803B9
(en)
|
2005-08-18 |
2013-05-30 |
Genmab A/S |
Therapy with CD4 binding peptides and radiation
|
|
RU2482132C2
(ru)
|
2005-08-26 |
2013-05-20 |
Роше Гликарт Аг |
Модифицированные антигенсвязывающие молекулы с измененной клеточной сигнальной активностью
|
|
EP1973950B1
(en)
|
2006-01-05 |
2014-09-17 |
Genentech, Inc. |
Anti-ephb4 antibodies and methods using the same
|
|
WO2007109052A2
(en)
|
2006-03-16 |
2007-09-27 |
Genentech, Inc. |
Methods of treating lupus using cd4 antibodies
|
|
EP2010569A4
(en)
|
2006-03-20 |
2009-09-09 |
Xoma Technology Ltd |
HUMAN ANTIBODIES SPECIFIC TO GASTRINE MATERIALS AND METHODS
|
|
WO2007117602A2
(en)
|
2006-04-07 |
2007-10-18 |
Biogen Idec Ma Inc. |
Isolation and use of human regulatory t cells
|
|
GEP20125628B
(en)
|
2006-04-21 |
2012-09-10 |
Novartis Ag |
Pharmaceutical compositions containing antagonist anti-cd40 antibody
|
|
WO2007135684A2
(en)
*
|
2006-05-22 |
2007-11-29 |
Hadasit Medical Research Services & Development Limited |
Method of treatment of anti-cd4 autoimmunity
|
|
US8557533B2
(en)
|
2007-02-01 |
2013-10-15 |
Helmut Jonuleit |
Screening method for the identification of agents capable of activating CD4+CD25+ regulatory T-cells through interactions with the HIV-1 GP120 binding site on CD4
|
|
WO2008134046A1
(en)
|
2007-04-27 |
2008-11-06 |
Genentech, Inc. |
Potent, stable and non-immunosuppressive anti-cd4 antibodies
|
|
PL2262838T3
(pl)
|
2008-03-13 |
2016-10-31 |
|
Środek do leczenia choroby
|
|
AU2009224690B2
(en)
|
2008-03-13 |
2014-10-09 |
Biotest Ag |
Agent for treating disease
|
|
CN102027017A
(zh)
|
2008-03-13 |
2011-04-20 |
生物测试股份公司 |
一种治疗疾病的试剂
|
|
EP2101173A1
(en)
|
2008-03-14 |
2009-09-16 |
Vivalis |
In vitro method to determine whether a drug candidate active against a target protein is active against a variant of said protein
|
|
US8951793B2
(en)
|
2008-08-21 |
2015-02-10 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Method of making an isolated population of FOXP3+ regulatory T cells
|
|
ES2335381B1
(es)
|
2008-09-24 |
2011-02-28 |
Fundacio Institut De Recerca De L'hospital Universitari Vall D'hebron |
Metodo in vitro y kit para el pronostico o prediccion de la respuestapor parte de pacientes con artritis reumatoide al tratamiento con agentes bloqueantes del factor tnfalfa.
|
|
BRPI0919489A2
(pt)
|
2008-09-29 |
2015-12-01 |
Biotest Ag |
composição, kit, métodos de tratamento de uma doença reumática, e de artrite reumatóide em um paciente, agente capaz de ativar células t reguladoras cd4+cd25+ e metotrexato, e, uso de um agente capaz de ativar células t reguladoras cd4+cd25+ e metotrexato
|
|
ES2351456B1
(es)
|
2009-06-24 |
2011-11-28 |
Fundacio Institut De Recerca De L'hospital Universitari Vall D'hebron |
Metodo in vitro para el pronostico o prediccion de la respuesta por parte de pacientes con artritis reumatoide al tratamiento con agentes que reconocen el receptor de membrana cd20 de los linfocitos b
|
|
JP5399219B2
(ja)
|
2009-11-24 |
2014-01-29 |
株式会社ケイティーバイオ |
関節リウマチに対するヒト型抗ＴＮＦα抗体薬の薬効予測方法、及び薬効予測装置
|
|
WO2011158798A1
(ja)
|
2010-06-14 |
2011-12-22 |
国立大学法人山口大学 |
乾癬治療効果の経過観察及び早期の予測方法並びにそれらに使用するキット
|